The company said, “November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer- especially prostate and skin cancer, which are among the most common cancers affecting men. In advanced prostate cancer, lifelong treatment modalities are making a difference, yet challenges remain for patients with a high cardiovascular risk profile linked to hormone deprivation therapies.” “While hormone deprivation therapy has long been the standard for advanced prostate cancer, most of the drugs in this category can raise cardiovascular risks,” explained Dr. Raza Bokhari, Executive Chairman & CEO. “Medicus Pharma (MDCX) is developing next-generation hormone deprivation therapies for advanced stage prostate cancer that may protect the heart while effectively controlling the cancer.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma files to sell 2.68M common shares for holders
- Is MDCX a Buy, Before Earnings?
- Optimistic Buy Rating for Medicus Pharma Ltd Driven by Promising SkinJect Developments and Strategic Initiatives
- Medicus Pharma Seeks FDA Priority Voucher for Innovative Skin Cancer Treatment
- Medicus Pharma announces filing of CNPV application for SKNJCT-003